IL1B and COVID-19: Targeting the NLRP3/IL-1 pathway by administering anakinra, the recombinant version of IL-1 receptor antagonist might block this noxious circuit and has proved beneficial in COVID-19 patients with a favorable safety profile [54,56,57,58,59].